By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS








Company News
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4. 1/9/2017 8:29:39 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Intent To Grant Patent In EU For Treating Neural Injury With Thymosin Beta 4 12/16/2016 8:00:54 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces First Patients Enrolled In Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) With RGN-259 11/10/2016 3:14:47 PM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Allowance For Patent For Tß4 Eye Drop Formulation 11/3/2016 6:58:29 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Joint Venture Initiates Second Phase 3 Study Of RGN-259 For Dry Eye Syndrome 9/30/2016 10:51:43 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) To Present At Rodman & Renshaw 18th Annual Global Investment Conference 8/30/2016 11:55:17 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Intent To Grant Patent For The Treatment Of Patients With Multiple Sclerosis In EUrege 8/29/2016 8:45:28 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Joint Venture To Begin Second Phase 3 Study Of RGN-259 For Dry Eye Syndrome In 3rd Quarter 8/24/2016 7:07:21 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Allowance For Key U.S. Patent That Expands And Extends Exclusivity Of Company's Product Candidates 8/3/2016 12:20:48 PM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces $1.75 Million Private Placement 6/27/2016 8:46:01 AM
12345678910...
//-->